BBOT BridgeBio Oncology Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1869105 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-49.2%
TTM EPS YoY100.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-46.4%
ROA-41.3%
ROIC (approx.)-116.1%
Asset turnover—
Leverage & solvency
Liabilities / assets15.3%
Debt / equity0.00x
Current ratio4.08x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.88x
Accruals ratio-5.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $29.59M | $49.23M | $39.80M | $38.07M | $35.05M | $27.44M | $20.64M | $19.54M |
| SG&A expense | $7.89M | $10.96M | $6.38M | $5.33M | $14.13M | $2.65M | $2.50M | $2.34M |
| Operating income | -$37.49M | -$60.19M | -$46.18M | -$43.41M | -$49.18M | -$30.09M | -$23.14M | -$21.88M |
| Income tax | $0 | $0 | — | $0 | $0 | $0 | $0 | $0 |
| Net income | -$34.18M | -$56.45M | -$42.11M | -$38.80M | -$44.76M | -$28.43M | -$22.05M | -$19.69M |
| EBITDA | -$37.39M | -$60.09M | -$46.10M | -$43.32M | -$49.08M | -$29.99M | -$23.08M | -$21.83M |
| EPS (basic) | -0.43 | -705.20 | -526.11 | — | -1.03 | -566.46 | -54.23 | — |
| EPS (diluted) | -0.43 | -705.20 | -526.11 | — | -1.03 | -566.46 | -54.23 | — |
| Weighted avg. shares (diluted) | 80.18M | 80.05M | 80,032 | — | 43.49M | 50.20M | 406,723 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $76.48M | $54.06M | $52.66M | $373.69M | $408.87M | $31.65M | $26.35M | $30.98M |
| Short-term investments | $117.39M | $171.65M | $199.62M | $51.77M | $59.54M | — | — | $124.78M |
| Current assets | $208.33M | $242.38M | $266.50M | $432.40M | $476.01M | $876,779 | $1.24M | $158.69M |
| PP&E, net | $815,000 | $878,000 | $938,000 | $956,000 | $827,000 | — | — | $490,000 |
| Total assets | $346.22M | $376.71M | $417.65M | $448.38M | $484.79M | $197.39M | $195.68M | $164.30M |
| Current liabilities | $51.03M | $51.63M | $43.26M | $35.04M | $35.71M | $2.63M | $1.87M | $19.58M |
| Total liabilities | $52.84M | $53.59M | $45.37M | $37.28M | $38.09M | $8.15M | $7.39M | $19.58M |
| Shareholders' equity | $293.39M | $323.11M | $372.28M | $411.10M | $446.70M | -$227.73M | -$200.03M | -$178.64M |
| Shares outstanding | 80.23M | 80.12M | 80.09M | 79.99M | 79.20M | — | — | 28,415 |
| Cash flow statement | ||||||||
| Operating cash flow | -$28.36M | -$44.36M | -$35.92M | -$42.23M | -$70.63M | -$23.29M | -$19.60M | -$15.04M |
| Capital expenditure | $13,000 | $47,000 | $24,000 | $73,000 | $140,000 | $231,000 | $162,000 | $10,000 |
| Free cash flow | -$28.38M | -$44.41M | -$35.94M | -$42.31M | -$70.77M | -$23.52M | -$19.76M | -$15.04M |
| Investing cash flow | $50.34M | $45.73M | -$285.41M | $7.77M | $40.55M | $9.64M | $15.37M | $25.56M |
| Financing cash flow | $442,000 | $37,000 | $295,000 | -$586,000 | $365.44M | $18.96M | -$404,000 | $52,000 |
| Depreciation & amortization | $100,000 | $100,000 | $74,000 | $84,000 | $100,000 | $100,000 | $54,000 | $52,000 |
| Stock-based compensation | $4.75M | $7.23M | $3.87M | $2.95M | $1.43M | $875,000 | $627,000 | $587,000 |
Free plan shows the latest 8 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.